Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Liver cancer is one of the most prevalent forms of cancer of the digestive system in our country. The most common subtype of this disease is hepatocellular carcinoma (HCC). Currently, treatment options for HCC patients include surgical resection, liver transplantation, radiofrequency ablation, chemoembolization, and biologic-targeted therapy. However, the efficacy of these treatments is suboptimal, as they are prone to drug resistance, metastasis, spread, and recurrence. These attributes are closely related to cancer stem cells (CSCs). Therefore, the utilization of drugs targeting CSCs may effectively inhibit the development and recurrence of HCC.
METHODS: HepG2 and Huh7 cells were used to analyze the antitumor activity of emodin by quantifying cell growth and metastasis, as well as to study its effect on stemness.
RESULTS: Emodin effectively suppressed the growth and movement of HCC cells. Emodin also significantly inhibited the proliferation of CD44-positive hepatoma cells.
CONCLUSION: Emodin shows promise as a potential therapeutic agent for HCC by targeting CD44-- positive hepatoma cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Current cancer drug targets - (2023) vom: 20. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gao, Yuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Emodin; Liver cancer; Hepatocellular carcinoma; Stemness; Cancer stem cells; CD44 |
|---|
| Anmerkungen: |
Date Revised 15.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0115680096256913231101103719 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365902187 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365902187 | ||
| 003 | DE-627 | ||
| 005 | 20231227132533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0115680096256913231101103719 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1228.xml |
| 035 | |a (DE-627)NLM365902187 | ||
| 035 | |a (NLM)38099524 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gao, Yuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Liver cancer is one of the most prevalent forms of cancer of the digestive system in our country. The most common subtype of this disease is hepatocellular carcinoma (HCC). Currently, treatment options for HCC patients include surgical resection, liver transplantation, radiofrequency ablation, chemoembolization, and biologic-targeted therapy. However, the efficacy of these treatments is suboptimal, as they are prone to drug resistance, metastasis, spread, and recurrence. These attributes are closely related to cancer stem cells (CSCs). Therefore, the utilization of drugs targeting CSCs may effectively inhibit the development and recurrence of HCC | ||
| 520 | |a METHODS: HepG2 and Huh7 cells were used to analyze the antitumor activity of emodin by quantifying cell growth and metastasis, as well as to study its effect on stemness | ||
| 520 | |a RESULTS: Emodin effectively suppressed the growth and movement of HCC cells. Emodin also significantly inhibited the proliferation of CD44-positive hepatoma cells | ||
| 520 | |a CONCLUSION: Emodin shows promise as a potential therapeutic agent for HCC by targeting CD44-- positive hepatoma cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Emodin; Liver cancer; Hepatocellular carcinoma; Stemness; Cancer stem cells; CD44 | |
| 700 | 1 | |a Li, Youling |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Yunhe |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Qiao |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a du, Boyu |e verfasserin |4 aut | |
| 700 | 1 | |a Xi, Xueyan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Gang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g (2023) vom: 20. Nov. |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:20 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115680096256913231101103719 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 20 |c 11 | ||